ID | 114195 |
Author |
Kajikawa, Masato
Hiroshima University
Maruhashi, Tatsuya
Hiroshima University
Hidaka, Takayuki
Hiroshima University
Matsui, Shogo
Hiroshima University
Hashimoto, Haruki
Hiroshima University
Takaeko, Yuji
Hiroshima University
Nakano, Yukiko
Hiroshima University
Kurisu, Satoshi
Hiroshima University
Kihara, Yasuki
Hiroshima University
Mohamad Yusoff, Farina
Hiroshima University
Kishimoto, Shinji
Hiroshima University
Chayama, Kazuaki
Hiroshima University
Goto, Chikara
Hiroshima International University
Noma, Kensuke
Hiroshima University
Nakashima, Ayumu
Hiroshima University
Hiro, Takafumi
Nihon University
Hirayama, Atsushi
Nihon University
Shiina, Kazuki
Tokyo Medical University
Tomiyama, Hirofumi
Tokyo Medical University
Yagi, Shusuke
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Amano, Rie
The University of Tokushima
Yamada, Hirotsugu
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sata, Masataka
The University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Higashi, Yukihito
Hiroshima University
|
Content Type |
Journal Article
|
Description | The dipeptidyl peptidase-4 inhibitor saxagliptin is a widely used antihyperglycemic agent in patients with type 2 diabetes. The purpose of this study was to evaluate the effects of saxagliptin on endothelial function in patients with type 2 diabetes. This was a prospective, multicenter, interventional study. A total of 34 patients with type 2 diabetes were enrolled at four university hospitals in Japan. Treatment of patients was initially started with saxagliptin at a dose of 5 mg daily. Assessment of endothelial function assessed by flow-mediated vasodilation (FMD) and measurement of stromal cell-derived factor-1α (SDF-1α) were conducted at baseline and at 3 months after treatment with saxagliptin. A total of 31 patients with type 2 diabetes were included in the analysis. Saxagliptin significantly increased FMD from 3.1 ± 3.1% to 4.2 ± 2.4% (P = 0.032) and significantly decreased total cholesterol from 190 ± 24 mg/dL to 181 ± 25 mg/dL (P = 0.002), glucose from 160 ± 53 mg/dL to 133 ± 25 mg/dL (P < 0.001), HbA1c from 7.5 ± 0.6% to 7.0 ± 0.6% (P < 0.001), urine albumin-to-creatinine ratio from 63.8 ± 134.2 mg/g to 40.9 ± 83.0 mg/g (P = 0.043), and total SDF-1α from 2108 ± 243 pg/mL to 1284 ± 345 pg/mL (P < 0.001). These findings suggest that saxagliptin is effective for improving endothelial function.
|
Journal Title |
Scientific Reports
|
ISSN | 20452322
|
Publisher | Springer Nature
|
Volume | 9
|
Start Page | 10206
|
Published Date | 2019-07-15
|
Rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
University Hospital
|